2901 South Loop Drive
214 articles with NewLink Genetics
- Combined company, Lumos Pharma, Inc., to trade on Nasdaq under the stock symbol “LUMO” - Phase 2b trial expected to be initiated mid-2020 evaluating oral therapeutic candidate LUM-201 (ibutamoren) in Pediatric Growth Hormone Deficiency (PGHD) - Projected combined cash on March 31, 2020 in excess of $80 million expected to be sufficient to fund company through Phase 2b trial in PGHD data read-out
3/9/2020Although March looks to be a busy month for the U.S. Food and Drug Administration, several of the PDUFA dates for this week were for drugs under Priority Review.
NewLink Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate UpdateSpecial Meeting of Stockholders set for March 17, 2020 for vote on proposed merger of NewLink Genetics and Lumos Pharma
NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on corporate activities.
NewLink Genetics Announces Exclusive Worldwide License Agreement with Ellipses Pharma for Development of and Rights to Commercialization of NLG207
NewLink Genetics Corporation announced that the company has entered into an exclusive worldwide license agreement with Ellipses Pharma Limited for the development of and rights to commercialize NLG207, a nanoparticle formulation of the topoisomerase 1 inhibitor camptothecin.
NewLink Genetics Corporation (NASDAQ:NLNK) announced today that, after priority review, the FDA has granted approval of ERVEBO®, or Zaire Ebola virus vaccine V920 (rVSV∆G-ZEBOV-GP), as confirmed by our partner, Merck (NYSE:MRK), known as MSD outside the US and Canada.
NewLink Genetics Reports Third Quarter 2019 Financial Results and Provides Corporate UpdateManagement to host conference call today at 8:30 a.m. ET
NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the third quarter ended September 30, 2019 and provided an update on corporate activities.
NewLink Genetics Corporation announced it will host its third quarter 2019 conference call and webcast at 8:30 AM ET on Wednesday, November 6, 2019, to discuss its third quarter financial results and provide an update on corporate activities.
NewLink Genetics Announces EU Regulatory Committee (CHMP) Recommendation for Conditional Marketing Authorization for Ebola Vaccine V920 (ERVEBO®)
This Committee recommendation will now be reviewed by the European Commission which, if it chooses to affirm the CHMP’s recommendation, will grant a centralized marketing authorization of the vaccine under a unified label valid in 31 European countries.
NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting
Updated Phase 1 data for indoximod plus standard-of-care chemotherapy in newly diagnosed AML show post-induction minimal residual disease (MRD) negativity rate of 86% and post-consolidation MRD negativity of 100%
11/12/2018As an outbreak of the Ebola virus in the Democratic Republic of the Congo worsens, a team of health officials has taken four experimental vaccines to the front lines and begun to administer it to patients who may have been exposed to the deadly virus.
NewLink Genetics Announces Indoximod Biomarker Data and Prodrug NLG802 Pharmacokinetic Data to be Presented at SITC 2018
NewLink Genetics Corporation announced today that two abstracts were accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting being held November 7-11, 2018 in Washington, D.C.
NewLink Genetics has announced, with the company restructuring and layoffs, they are refocusing on indoximod.
NewLink Genetics Announces Clinical Plan, Reports Second Quarter 2018 Financial Results and Revises Cash GuidanceManagement to Host Conference Call Today at 4:30 p.m. ET
NewLink Genetics Corporation announced its clinical plan and strategy, reported consolidated financial results for the second quarter of 2018, and revised its cash guidance.
NewLink Genetics Corporation announced that it will release its second quarter 2018 financial results on Tuesday, July 31, 2018.
Ebola cases, as well as cases of other significantly lethal viral outbreaks that have occurred has spurred researchers to focus on the development of antivirals that can treat the illnesses.
NewLink Genetics Announces Positive Updated Phase 1 Data with Indoximod Plus Radio-Immunotherapy for Pediatric Patients with DIPG Presented at ISPNO 2018
NewLink Genetics Corporation reported that updated Phase 1 data evaluating indoximod plus front-line radiation and maintenance chemotherapy were presented Sunday, July 1, at the ISPNO 2018 Annual Meeting.
NewLink Genetics Announces Updated Data for Indoximod Plus Radio-Immunotherapy in DIPG to be Presented at ISPNO 2018 Meeting
NewLink Genetics Corporation announced that updated data for patients with diffuse intrinsic pontine glioma (DIPG) from NLG2105, a Phase 1 study evaluating indoximod in combination with radiation and chemotherapy for the treatment of pediatric patients with progressive brain tumors, will be presented at the International Symposium on Pediatric Neuro-Oncology (ISPNO)
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
NewLink Genetics Announces Final Results from Two Phase 2 Studies of Indoximod Presented at ASCO 2018
NewLink Genetics Corporation announced that data from two Phase 2 studies of indoximod, used in combination with other agents, were presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Genentech, has terminated its research program with Ames, Iowa-based NewLink Genetics.